6094-60-6

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-4-cyano-4-hydroxypiperidine is used as a precursor in the synthesis of Isoxazole Carboxamide compounds for the treatment of hearing loss and balance disorders. Its unique structure allows for the development of therapeutic agents that can target specific pathways and mechanisms involved in these conditions, offering potential benefits to patients suffering from such disorders.

InChI:InChI=1/C13H16N2O/c14-11-13(16)6-8-15(9-7-13)10-12-4-2-1-3-5-12/h1-5,16H,6-10H2

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 
• 7677-24-9 trimethylsilyl cyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 235100-94-4 1-benzyl-4-cyano-4-methanesulfonyloxypiperidine 
• 59119-18-5 1-benzyl-4-hydroxypiperidine-4-carboxylic acid 
• 60437-30-1 4-hydroxy-4-(methoxycarbonyl)-1-(phenylmethyl)piperidine 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 13801-04-2 1-benzyl-4-morpholin-4-yl-piperidine-4-carbonitrile 
• 930604-02-7 1-benzyl-4-(4-methyl-piperazin-1-yl)-piperidine-4-carbonitrile 
• 495415-09-3 1-tert-butyl 4-methyl 4-hydroxypiperidine-1,4-dicarboxylate 
• 23781-00-2 ethyl 1-benzyl-4-hydroxypiperidine-4-carboxylate 
• 118937-10-3 8-benzyl-3-(3-chlorophenyl)-4-<<(3-chlorophenyl)carbamoyl>imino>-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 26733-62-0 8-benzyl-1-oxa-3,8-diaza-spiro[4.5]decane-2,4-dione 
• 84254-97-7 1'-benzyl-octahydro-[1,4']bipyridinyl-4'-carbonitrile 
• 60437-28-7 3-benzoyl-8-benzyl-4-imino-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 60437-25-4 8-benzyl-4-imino-3-methyl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 60437-27-6 3-acetyl-8-benzyl-4-imino-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 

Relevant academic research and scientific papers

ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF

A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.

PHENOTHIAZINE DERIVATIVES AND USES THEREOF

The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).

Identification of spirooxindole and dibenzoxazepine motifs as potent mineralocorticoid receptor antagonists

Mineralocorticoid receptor (MR) antagonists continue to be a prevalent area of research in the pharmaceutical industry. Herein we report the discovery of various spirooxindole and dibenzoxazepine constructs as potent MR antagonists. SAR analysis of our spirooxindole hit led to highly potent compounds containing polar solubilizing groups, which interact with the helix-11 region of the MR ligand binding domain (LBD). Various dibenzoxazepine moieties were also prepared in an effort to replace a known dibenzoxepane system which interacts with the hydrophobic region of the MR LBD. In addition, an X-ray crystal structure was obtained from a highly potent compound which was shown to exhibit both partial agonist and antagonist modes of action against MR.

Anesthetic compounds and related methods of use

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE

Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.

PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF

A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

DIAZASPIRODECANE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to diazaspirodecane compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Oxazolones as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1

2,5,5-Trisubstituted oxazolones were identified as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The synthesis, structure-activity relationship and metabolic stability of these compounds are presented.

Spiro-rifamycin derivatives targeting RNA polymerase

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.